Biolase (BIOL) Reports In-Line Q4 EPS, Miss on Revenues

Note: EPS may not be comparable

Biolase (NASDAQ: BIOL) reported Q4 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $12.63 million versus the consensus estimate of $13.83 million.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
• Simmons First National Corp (SFNC) Misses Q1 EPS by 1c
• Helen of Troy (HELE) Tops Q4 EPS by 15c, Beats on Revenue; Offers FY25 EPS Guidance